Alentis Therapeutics is thrilled to announce the successful completion of a $100 million funding round, significantly bolstering our efforts to revolutionize the treatment landscape for CLDN1-positive tumors and organ fibrosis. As a clinical-stage biotechnology company, Alentis is dedicated to pioneering first-in-class antibodies and antibody-drug conjugates (ADCs) specifically targeting CLDN1—an underexplored key player in the pathology of various cancers and fibrotic diseases. Our innovative approach utilizes a portfolio of anti-CLDN1 monoclonal antibodies to reprogram the tumor microenvironment (TME), aiming to dismantle the protective barriers that cancer cells utilize to evade immune attacks. With our lead oncology asset, ALE.C04, we are on the brink of introducing the first therapeutic option focused on CLDN1 in solid tumors. Additionally, our ongoing Phase 1 clinical trial for ALE.F02 showcases our commitment to combatting organ fibrosis by targeting the pathological overexpression of CLDN1 outside of tight junctions. This investment will propel our research and clinical development efforts, accelerating the journey from laboratory breakthroughs—originating from the pioneering research of Prof. Thomas Baumert MD at the University of Strasbourg—to effective treatments that can change patients' lives. Headquartered in Basel’s pharmaceutical hub, Alentis is poised for significant advancements in a market devoid of existing options for CLDN1-targeted therapies. We are excited to leverage these resources to fulfill our mission and contribute meaningfully to the diverse and complex challenges faced in the realms of oncology and fibrosis. For more information, visit www.alentis.ch or contact us at info@alentis.ch.
Alentis Therapeutics Secures $100 Million in Series A Funding for Groundbreaking Anti-CLDN1 Cancer and Fibrosis Treatments
Recently funded · $100.0M Series aBiotechnology
Get the full C Ray Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
